NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat ...
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations ...
REVERSE-IT is PhaseBio’s ongoing pivotal Phase 3 trial of its lead product bentracimab, which is designed to study the reversal of the antiplatelet effects of ticagrelor in patients who present either ...
-First clinical evaluation of BB-025, designed to rapidly and specifically reverse BB-031 activity, advancing Basking's goal to redefine thrombosis treatment- RESEARCH TRIANGLE, N.C., Nov. 12, 2025 ...
MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and ...
The last volunteer was enrolled in the REVERSE-IT study; recruitment of the 600 participants in this international, multicenter, randomized, placebo-controlled clinical study is complete. This Phase ...
-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results